Introduction {#Sec1}
============

China has the world's largest type 2 diabetes mellitus (T2DM) population (114.4 million), with an estimated overall prevalence of 10.9% reported in Chinese adults in 2017 \[[@CR1]\]. Despite the availability of several antidiabetes drugs, only 47.7% of patients with T2DM achieve the target glycated hemoglobin (HbA1c) levels (\< 7%) in China \[[@CR2]\]. The China DiaSTAGE study suggested that poor target achievement in Chinese patients with T2DM \> 65 years of age could be due, at least in part, to age, duration of T2DM, body mass index (BMI), HbA1c control, and hypoglycemia events; meanwhile, inadequate glycemic control in these patients might also be due to the use of insulin secretagogues \[[@CR3]\].

At present, lifestyle modifications and metformin are the first-line treatment strategies for T2DM \[[@CR4]\]. Nevertheless, studies have shown that there is a progressive loss of glycemic control with prolonged use of metformin, leading to unsatisfactory long-term outcomes \[[@CR5], [@CR6]\]. The 2017 Chinese Guidelines for the Prevention and Treatment of T2DM emphasized the importance of using two oral antidiabetes drugs (OADs) \[[@CR7]\]. The 2019 American Diabetes Association Guideline also suggested that two OADs should be initially administered in patients with newly diagnosed T2DM and HbA1c levels \> 9% \[[@CR4]\]. In addition, the 2019 American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) T2DM management guidelines suggested that combination therapy of metformin with other OADs such as glucagon-like peptide 1 (GLP-1) agonists, sodium-dependent glucose transporter 2 (SGLT2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones (TZD), insulin, alpha-glycosidase inhibitors, sulfonylureas, or glinides should be considered in selected patients on an individual basis \[[@CR8]\]. Hence, it is important to consider the addition of a second OAD for the optimization of glycemic control, but the risk of adverse events (such as hypoglycemia and weight gain) has to be carefully weighed against the benefits.

Vildagliptin is a potent and selective DPP-4 inhibitor that increases α- and β-cell responsiveness to glucose, without weight gain or increased risk of hypoglycemia \[[@CR9], [@CR10]\]. The efficacy and safety of vildagliptin alone or with metformin have been well established in randomized controlled trials (RCTs) in predominately Caucasians \[[@CR11], [@CR12]\], but it is still unknown whether these findings can be extrapolated to the real-world setting in Chinese patients with T2DM.

The China Prospective Diabetes Study (China PDS) is a post-marketing, prospective, multicenter, observational, real-world study designed to evaluate the effectiveness and safety of vildagliptin add-on to metformin for the treatment of T2DM patients in China.

Methods {#Sec2}
=======

Study Design and Subjects {#Sec3}
-------------------------

This study was conducted between June 2013 and April 2017 in 52 centers of China. The study was approved by the ethics committees of all participating institutions (Supplementary Table 1). Chinese PLA General Hospital piloted the ethical review of this study. Informed consent for the study was obtained from all participants. The study was conducted in compliance with the Helsinki Declaration of 1964 and its later amendments. The eligibility criteria were (1) age ≥ 18 years; (2) diagnosed with T2DM; 3) recent (\< 3 months) HbA1c measurement between 7% and 11%; (4) received oral monotherapy with sulfonylurea, metformin, TZD, or alpha-glycosidase inhibitors; and (5) plan to initiate a second OAD on the basis of the local physician's decision. Patients were excluded from the study if they (1) had participated in any RCT; (2) had been treated with insulin and/or GLP-1 analogue or agonist, and/or OAD single-pill combination (SPC), or planned to initiate any of the aforementioned drugs after enrollment; (3) were diagnosed with type 1 diabetes mellitus; (4) were pregnant or lactating; or (5) were unable to undergo regular follow-up on the basis of the investigator's judgment, including non-resident and other factors.

The local physician chose the OADs at their discretion. To ensure the non-interventional status of the study, patient enrollment was carried out after the treatment decision had been made. Among all patients enrolled in the China PDS, patients initiated treatment with vildagliptin add-on to metformin (VM cohort) or any two OADs other than vildagliptin (comparator cohort) were included in the present analysis.

Data Collection {#Sec4}
---------------

Data were recorded using an electronic case report form (eCRF) and collected by using an electronic data capture (EDC) system. Medications were recorded in the database by using the World Health Organization (WHO) drug reference directory. Adverse events (AEs) were recorded by using Medical Dictionary for Regulatory Activities (MedDRA) version 15.1.

The patient demographic characteristics included age, gender, BMI, ethnicity, baseline HbA1c, duration of T2DM, complications, smoking history, and T2DM family history.

Follow-up and Endpoints {#Sec5}
-----------------------

The composite primary endpoint was defined as good glucose control (HbA1c \< 7%) without any tolerability event after 12 months of treatment (i.e., treatment success). The tolerability events included hypoglycemia (presence of symptoms suggestive of hypoglycemia, confirmed by self-monitored glucose \< 3.1 mmol/L, and symptom relief after consuming carbohydrates \[[@CR13]\]), clinically significant weight gain (weight gain ≥ 3% based on National Institutes of Health (NIH) guidelines \[[@CR14], [@CR15]\]), and discontinuation due to gastrointestinal (GI) events (such as decreased or increased appetite, abdominal pain, diarrhea, nausea, vomiting, dry mouth, dyspepsia, and weight loss \[[@CR16]\]).

The secondary endpoints were (1) the mean changes in HbA1c from baseline to 3, 6, and 12 months; (2) glucose control (HbA1c \< 7%) at 3, 6, and 12 months; (3) safety and tolerability; (4) the success rate of the composite endpoint according to the geographic region (eastern China, northern China, and southern China), BMI subgroups (BMI \< 24, 24--28, and \> 28 kg/m^2^), baseline HbA1c subgroups (HbA1c \< 8%, 8--9%, and \> 9%), the non-prespecified subgroups (including age, gender, duration of T2DM, T2DM complication, smoking history, and T2DM family history); (5) the success rate of the composite endpoint and the proportion of patients achieving HbA1c \< 7% after 3, 6, and 12 months in the VM cohort versus insulin-secreting agent add-on to metformin (IM) subgroup of the comparator cohort; and (6) the success rate of the composite endpoint and the proportion of patients achieving HbA1c \< 7% after 3, 6, and 12 months in the VM cohort versus α-glucosidase inhibitor add-on to metformin (AM) subgroup of the comparator cohort.

The safety outcomes, as evaluated by vital sign, physical and lab examinations, included all AEs recorded during OAD treatment in the VM and comparator cohorts.

Statistical Analysis {#Sec6}
--------------------

Sample size calculation was based on the success rates of the composite primary endpoint in the VM cohort (34.0%) and comparator cohort (21.3%) (estimation based on the EDGE study \[[@CR17]\]). The two-sided *Z* test was used, with *α* = 0.05 and *β* = 90%. At a dropout rate of 20%, 321 subjects were required for the VM cohort and 217 subjects were required for the comparator cohort.

The full analysis set (FAS) included all patients in the VM or comparator cohorts with at least one effectiveness evaluation after baseline and before therapy change. The safety analysis set (SAS) included all patients who participated in this study and had at least one safety evaluation after baseline.

Propensity score matching (PSM) was carried out to adjust for baseline covariates between the VM and comparator cohorts on the basis of BMI and HbA1c.

Continuous variables are presented as means and standard deviations (SD) and were analyzed using the Mann--Whitney *U* test. Categorical variables are presented as frequencies and were analyzed using the chi-square test. *P* values \< 0.05 were considered statistically significant on the basis of two-tailed tests. Odds ratio (OR) was used to compare treatment success and relative risk (RR) was used to compare treatment safety between the two cohorts; ORs and RRs are presented with the corresponding 95% confidence intervals (CIs). All statistical analyses were performed using SAS 9.2 (SAS Institute, Cary, NY, USA).

Results {#Sec7}
=======

Baseline Characteristics {#Sec8}
------------------------

From June 2013 to April 2017, 1657 patients were enrolled. After exclusion of patients with eligibility violation (*n* = 2) and no follow-up data (*n* = 160), a total of 1495 patients were included for analysis. The SAS included 724 patients in the VM cohort and 771 in the comparator cohort. The FAS included 604 patients in the VM cohort and 670 in the comparator cohort (Fig. [1](#Fig1){ref-type="fig"}). After PSM, there were 530 (87.7%) patients in the VM cohort and 530 (79.1%) in the comparator cohort. The mean follow-up period was 12 ± 2 months. The detailed OAD treatment regimens prescribed in the real-life setting are shown in Supplementary Table 2. The most common vildagliptin dual therapies were vildagliptin plus metformin (64.7%), followed by vildagliptin plus sulfonylurea (SUs 14.7%) and vildagliptin plus α-glucosidase inhibitor (13.0%). The most common dual therapies excluding vildagliptin were metformin plus SUs (37.8%) and metformin plus α-glucosidase inhibitor (23.7%).Fig. 1Flowchart

The demographic characteristics of the patients before and after PSM are shown in Table [1](#Tab1){ref-type="table"}. Before PSM, age was 51.8 ± 11.0 years for the VM cohort and 57.7 ± 12.5 years for the comparator cohort (*P* \< 0.001). The proportion of male patients (61.9% vs. 56.3%, *P* \< 0.05), baseline HbA1c levels (8.32 ± 1.05% versus 8.06 ± 0.92%, *P* \< 0.001), and BMI (26.4 ± 3.9 kg/m^2^ vs. 25.3 ± 3.4 kg/m^2^, *P* \< 0.001) were higher in the VM cohort. The duration of T2DM in the VM cohort was shorter than that in comparator cohort (50.6 ± 55.1 months vs. 72.8 ± 66.3 months, *P* \< 0.001). After PSM, there were no significant differences in the baseline HbA1c (8.17 ± 0.96% vs. 8.20 ± 0.95%) and BMI (25.9 ± 3.1 kg/m^2^ vs. 25.8 ± 3.1 kg/m^2^) between the VM and comparator cohorts (*P* \> 0.05).Table 1Demographic characteristics of patients before and after PSM (full analysis set)ParameterMatched cohortFull cohortVM (*n* = 530)Comparator (*n* = 530)*P*VM (*n* = 604)Comparator (*n* = 670)*P*Age, years52.0 ± 10.857.1 ± 12.2\< 0.00151.8 ± 11.057.7 ± 12.5\< 0.001Gender (male), *n* %323 (60.9)306 (57.7)0.288374 (61.9)377 (56.3)0.041BMI, kg/m^2^25.9 ± 3.125.8 ± 3.10.64726.4 ± 3.925.3 ± 3.4\< 0.001Ethnicity (Han), *n* %517 (97.5)515 (97.2)0.120589 (97.5)653 (97.5)0.466Baseline HbA1c,  %8.17 ± 0.968.20 ± 0.950.5218.32 ± 1.058.06 ± 0.92\< 0.001Duration of T2DM, months52.7 ± 55.969.7 ± 63.2\< 0.00150.6 ± 55.172.8 ± 66.3\< 0.001Complications, *n* %251 (47.4)237 (44.7)0.388322 (53.3)353 (52.7)0.823Smoking history, *n* %141 (26.6)134 (25.3)0.668172 (28.5)168 (25.1)0.254T2DM family history, *n* %216 (40.8)216 (40.8)0.393243 (40.2)270 (40.3)0.606Data are *n* (%) or mean ± SD*VM* vildagliptin add-on to metformin, *BMI* body mass index, *HbA1c* glycated hemoglobin, *T2DM* type 2 diabetes mellitus

Composite Endpoint {#Sec9}
------------------

Results of the composite primary endpoint and individual components of the composite endpoint after PSM are shown in Fig. [2](#Fig2){ref-type="fig"}. After 12 months of treatment, the success rate of the composite primary endpoint in the VM cohort was higher than that in the comparator cohort (50.9% vs. 33.0%, *P* \< 0.001; OR 2.10, 95% CI 1.64--2.70) (Fig. [2](#Fig2){ref-type="fig"}a). At 3 months, there was no statistical difference in the proportion of patients with HbA1c \< 7% between the two cohorts. This proportion showed no significant changes in the comparator cohort, but steadily increased thereafter in the VM cohort. At 6 months, the proportion of patients reaching HbA1c \< 7% was higher than that in comparator cohort (51.5% vs. 43.1%, *P* \< 0.01). At 12 months, the proportion of patients with HbA1c \< 7% in the VM cohort (54.3%) was significantly higher than that in the comparator cohort (41.7%) (*P* \< 0.001) (Fig. [2](#Fig2){ref-type="fig"}b).Fig. 2Composite primary endpoint and individual components of the composite endpoint in the vildagliptin add-on to metformin (VM) cohort and dual oral antidiabetes agent, non-vildagliptin combination therapy (comparator) cohort after propensity score matching (*n* = 530 per cohort, full analysis set). **a** Success rate of composite endpoint. **b** Proportion of patients with HbA1c \< 7%. **c** Proportion of patients with tolerability events. Success was defined as HbA1c \< 7% and without any tolerability event \[hypoglycemia, weight gain ≥ 3% and discontinuation due to gastrointestinal events\]. \**P* \< 0.01, \*\**P* \< 0.001, VM vs. comparator. OR odds ratio, RR relative risk

The mean changes in HbA1c in the VM and comparator cohorts at 3, 6, and 12 months from baseline after PSM are shown in Supplementary Fig. 1. At 6 and 12 months, the decrease in HbA1c from baseline in the VM cohort was more pronounced than that in the comparator cohort (3 months: − 1.12 ± 1.18% vs. − 0.95 ± 1.24%, *P* \< 0.01; 6 months: − 1.14 ± 1.29% vs. − 0.89 ± 1.31%, *P* \< 0.001).

The tolerability profile of the VM and comparator cohorts after PSM are shown in Fig. [2](#Fig2){ref-type="fig"}c. The occurrence rate of total tolerability events in the VM cohort (8.3%, 44/530) was lower than in the comparator cohort (16.2%, 86/530) after 12 months of treatment (RR 0.51, 95% CI 0.36--0.72). The rate of weight gain ≥ 3% in the VM cohort (7.9%, 42/530) was also lower than in the comparator cohort (14.2%, 75/530) (RR 0.56, 95% CI 0.39-0.80). The occurrence rate of hypoglycemic events in the VM cohort (0.4%, 2/530) was lower than in the comparator cohort (2.3%, 12/530) (RR 0.17, 95% CI 0.04--0.74).

Subgroup Analyses {#Sec10}
-----------------

Results of the composite endpoint from the prespecified subgroups analysis before PSM are shown in Fig. [3](#Fig3){ref-type="fig"}. Among the three geographic region subgroups, the success rates of the composite endpoint with VM in eastern China (OR 2.47, 95% CI 1.57--3.89), northern China (OR 1.69, 95% CI 1.18--2.42), and southern China (OR 3.43, 95% CI 1.22--9.67) were higher than with comparator.Fig. 3Subgroup analysis of composite endpoint before propensity score matching (full analysis set). Success was defined as HbA1c \< 7% and without any tolerability event (hypoglycemia, weight gain ≥ 3%, and discontinuation due to gastrointestinal events)

Among the three BMI subgroups, the success rates of the composite endpoint with VM in the BMI \< 24 kg/m^2^ (OR 1.65, 95% CI 1.08--2.50), 24--28 kg/m^2^ (OR 2.22, 95% CI 1.61--3.07), and \> 28 kg/m^2^ (OR 2.02, 95% CI 1.22--3.37) subgroups were all higher than with comparator.

Among the three baseline HbA1c subgroups, the success rates of the composite endpoint with VM in the HbA1c ≤ 8% (OR 2.17, 95% CI 1.60--2.93), \> 8--9% (OR 1.88, 95% CI 1.18--2.99), and \> 9% (OR 2.02, 95% CI 1.17--3.48) subgroups were all higher than with comparator.

Results of the composite endpoint from the non-prespecified subgroups analysis after PMS are shown in Supplementary Fig. 2. The success rates of the composite endpoint with VM in the age (except \> 75 years old), gender, duration of T2DM, complications, smoking history, and T2DM family history (except in unclear T2DM family history) subgroups were all higher than with comparator.

Analyses Based on IM and AM Subgroups of Comparator Cohort {#Sec11}
----------------------------------------------------------

The success rate of the composite endpoint and the proportion of patients reaching HbA1c \< 7% with VM and IM were compared after PSM (Fig. [4](#Fig4){ref-type="fig"}a, b). The success rate of the composite endpoint was 48.1% (154/320) with VM and 31.6% (101/320) with IM at 12 months (*P* \< 0.001; OR 2.01, 95% CI 1.45--2.77). The proportions of patients with HbA1c \< 7% were similar between the two cohorts at 3 months \[40.5% (115/284) with VM and 41.5% (125/301) with IM\]. The proportion increased steadily over time in the VM cohort, but not in the IM cohort. At 12 months, the proportion of patients reaching HbA1c \< 7% with VM (50.6%, 162/320) was significantly higher than with IM (39.7%, 127/320) (*P* \< 0.01).Fig. 4Composite endpoint and proportion of patients with HbA1c \< 7% in the vildagliptin add-on to metformin (VM) cohort and the α-glucosidase inhibitor add-on to metformin (AM) and insulin-secreting agent add-on to metformin (IM) cohorts after propensity score matching (full analysis set). **a**, **b** Success rate of composite endpoint and proportion of patients with HbA1c \< 7% in the VM and IM cohorts (*n* = 320 per cohort). **c**, **d** Success rate of composite endpoint and proportion of patients with HbA1c \< 7% in the VM and AM cohorts (*n* = 157 per cohort). Success was defined as HbA1c \< 7% and without any tolerability event (hypoglycemia, weight gain ≥ 3%, and discontinuation due to gastrointestinal events). \**P* \< 0.01, VM vs. IM. OR odds ratio

The success rate of the composite endpoint and the proportion of patients reaching HbA1c \< 7% were compared between the VM and AM cohorts after PSM (Fig. [4](#Fig4){ref-type="fig"}c, d). The success rate of the composite endpoint was 56.7% (89/157) with VM and 45.9% (72/157) with AM at 12 months (*P* = 0.055; OR 1.54, 95% CI 0.99--2.40). There were no significant differences in the proportion of patients with HbA1c \< 7% at 3, 6, or 12 months between the two cohorts (all *P* \> 0.05), but a trend of improved HbA1c control was observed for VM throughout the treatment period (3 months: 48.1% vs. 43.9%; 6 months: 57.8% vs. 49.4%, 12 months: 58.6% vs. 50.3%).

Safety {#Sec12}
------

Data on the occurrence of AE leading to treatment discontinuation in the safety set are shown in Table [2](#Tab2){ref-type="table"}. The rates of any AE were 8.3% (60/724) and 12.8% (99/771) in the VM and comparator cohorts, respectively. Hypoglycemia occurred in 0.3% (2/724) and 2.3% (18/771) in the VM and comparator cohorts, respectively.Table 2Adverse events in the VM and comparator cohorts (occurrence rate \> 0.5%, safety analysis set)Preferred terms in MedDRA classification systemVM (*n* = 724)Comparator (*n* = 771)*n* (%)Event frequency*n* (%)Event frequencyAny adverse event (overall)60 (8.3)7999 (12.8)131Metabolic and nutritional disorders2 (0.3)223 (3.0)29Hypoglycemia2 (0.3)218 (2.3)23Infections and infestations15 (2.1)2218 (2.3)23Upper respiratory tract infection8 (1.1)108 (1.0)11Investigations11 (1.5)118 (1.0)9Abnormal blood glucose9 (1.2)96 (0.8)7Nervous system disorders^a^3 (0.4)47 (0.9)8Injury, poisoning, and procedural complications3 (0.4)35 (0.6)5Musculoskeletal and connective tissue disorders4 (0.6)45 (0.6)5Skin and subcutaneous tissue disorders6 (0.8)64 (0.5)4Gastrointestinal disorders8 (1.1)811 (1.4)11Cardiac disorders1 (0.1)110 (1.3)12Eye disorders6 (0.8)75 (0.6)6VM vildagliptin add-on to metformin^a^Three cases each of stroke occurred in the VM and comparator cohorts

Discussion {#Sec13}
==========

The China PDS was a post-marketing, multicenter, prospective, observational, real-world study. The results showed that patients in the VM cohort had better glycemic control than the comparator cohort. In addition, the occurrence of tolerability events (hypoglycemia and weight gain ≥ 3%) in the VM cohort was significantly lower than in the comparator cohort after PSM.

As highlighted by the guidelines, T2DM treatment should be individualized according to each patient on the basis of desired efficacy, tolerance, safety, and treatment costs \[[@CR8]\]. In the present real-world study in China, our pre-PSM baseline showed that add-on vildagliptin was preferentially prescribed in patients with higher BMI, consistent with the EDGE study, a world-wide real-world study based on 43,791 patients with T2DM \[[@CR17]\]. Notably, the BMI in the VM cohort was lower than in other real-world studies \[[@CR17]--[@CR20]\]. This could be due to the threshold for overweight in Asians being lower than in other populations, especially in Caucasians \[[@CR21], [@CR22]\]. Furthermore, patients who received VM were younger, and had a shorter duration of T2DM and a higher baseline HbA1c in the present study, while no such trend was observed in the EDGE study \[[@CR17]\]. Notably, a regional difference in baseline characteristics was observed in the EDGE study, with younger age and shorter duration of disease reported in the developing countries and a relatively low baseline HbA1c reported for the East Asian population (South Korea and Philippines) \[[@CR23]\]. The baseline characteristics for our Chinese T2DM population were in general agreement with the profile reported for East Asians in the EDGE study \[[@CR23]\], suggesting an earlier onset of disease and early treatment intensification in the Chinese T2DM population. The differences in prescription patterns could be due to the different prescription preference of the physicians, patient ethnicity, and disease course in Eastern and Western countries. Other reasons for the differences in prescription pattern require further research.

Several studies have shown that the addition of vildagliptin to either high- or low-dose metformin provides superior efficacy compared with monotherapy and with an overall comparable tolerability profile. The potential dose-sparing effect of adding vildagliptin to low-dose metformin is preferred to an increased dose of metformin \[[@CR4], [@CR7]\]. This allows patients to achieve equivalent or superior HbA1c-lowering effects without the GI tolerability issues associated with higher doses of metformin \[[@CR24]\]. The EDGE study showed that after 12 months of treatment, 35% of patients achieved the glycemic goal on a vildagliptin-based combination treatment, which was better than those receiving other dual OAD treatment (23%) \[[@CR17]\] and that a consistent favorable HbA1c response was observed across all regions \[[@CR23]\]. A 2-year follow-up RCT of 3118 patients with T2DM also showed that vildagliptin was more effective in achieving a composite endpoint of HbA1c \< 7% without hypoglycemia or weight gain (29.8%) compared with glimepiride as add-on to metformin (19.4%) \[[@CR21]\]. Despite the different research designs, follow-up, and inclusion criteria, these studies all showed that the control of blood glucose after VM treatment was better than that after other dual OAD treatment. Our results further extended these previous observations by showing that VM was more effective than dual OAD non-vildagliptin combinations for T2DM in a real-world Chinese population. Notably, the present study showed higher success rates for the composite endpoint in both the VM and comparator cohorts than in the other studies \[[@CR17], [@CR21]\], which might be due to the relatively shorter duration of T2DM (around 4--5 years) in the present study.

In the subgroup analysis, we found that the success rate of the composite endpoint in the VM cohort was significantly higher than in the IM cohort and that the proportion of patients with glycemic control was retained for the VM cohort after 6 months, but not for the IM cohort. This suggests that the effectiveness of VM was better than for IM treatment in clinical practice, which is in line with the published RCTs \[[@CR22], [@CR25], [@CR26]\]. Among patients treated with IM, 76.7% (250/326) were on SU add-on to metformin and the diminished glycemic response observed in the IM cohort might be partially attributed to the suboptimal dose of SUs (due to fear of hypoglycemia) and the relatively longer duration of T2DM for the IM cohort \[[@CR27]\]. Indeed, the duration of glycemic lowering effect of SUs decreased with the duration of T2DM as a result of progressive deterioration in β-cell function. On the other hand, vildagliptin targets α-cells in addition to β-cells and may provide a prolonged glycemic response \[[@CR28]\]. The shorter durability of SUs as add-on to monotherapy compared with vildagliptin has also been reported in the EDGE study \[[@CR29]\]. Nevertheless, one large-scale retrospective cohort study reported improved durability of glycemic response with SUs versus DPP-4 inhibitors as add-on to metformin; the differences might be attributed to the differences in baseline BMI, HbA1c, and T2DM duration \[[@CR30]\].

In addition, guidelines for T2DM management also recommend avoiding side effects, particularly hypoglycemia and weight gain, when physicians make decisions about which antidiabetes drug to choose \[[@CR4], [@CR7], [@CR8]\]. In China, the most common dual therapy is insulin-secreting agent combined with metformin \[[@CR31]\]. This might be the main reason for the high incidence of hypoglycemia and weight gain in patients with T2DM in China. Hypoglycemia hampers effective glycemic control and may lead to the occurrence of serious complications including cardiovascular events \[[@CR8]\]. Severe hypoglycemia is also a key cause of death and disability in patients with T2DM. Hence, hypoglycemia is an important index for the clinical evaluation of OADs \[[@CR32]\]. The EDGE study showed that the incidence of hypoglycemia in the VM cohort (0.23%) was lower than in the dual OAD comparator cohort (1.28%) and the results of the present study are in line with the EDGE study \[[@CR33]\]. Indeed, in the present study, the incidence of hypoglycemia in the VM cohort (0.4%) was significantly lower than in the comparator cohort (2.3%). Of course, hypoglycemia events may be distressful and even represent some danger to the patient. Treatments associated with a lower risk of hypoglycemia events should be preferred in order to improve patient experience and safety \[[@CR4], [@CR7]\]. In a previous RCT, vildagliptin as add-on to metformin versus other drug combined with metformin led to markedly lower risks of hypoglycemia \[[@CR34]\]. Taken together, the literature and the present study suggest that vildagliptin is safe regarding the occurrence of hypoglycemia in clinical practice.

Weight loss is well established in the prevention of T2DM and is a critical component of T2DM management. Unfortunately, many traditional glucose-lowering drugs can lead to weight gain, which has a negative impact on the management of T2DM for most patients \[[@CR35], [@CR36]\]. Previous studies have shown that VM, compared to monotherapy, was more effective in reducing HbA1c levels and without weight gain \[[@CR24], [@CR37]\]. We found that the occurrence of ≥ 3% weight gain in the VM cohort was significantly lower than in the comparator cohort. This suggested the clinical benefits of VM treatment on body weight control compared to other non-vildagliptin dual OAD therapies.

GI events are common complications that occur during T2DM treatment. The most common untoward effects of α-glucosidase inhibitors in T2DM are GI events such as bowel gastroparesis, abdominal distention, abdominal pain, diarrhea, and increased GI exhaustion \[[@CR38]--[@CR40]\]. Moreover, in China, 10.9% of patients with T2DM receive α-glucosidase inhibitor and metformin therapy \[[@CR31]\], which may increase or aggravate GI events. As a DPP-4 inhibitor, vildagliptin shows a good glycemic control effect while it did not increase GI events in patients with T2DM in previous RCT studies \[[@CR40]\]. In the present study, we did not observe any discontinuation due to GI events, while the occurrence of GI disorders in the SAS population was similar. These low rates of occurrence of GI events are consistent with the results from the EDGE study (1.45% vs. 1.28%) \[[@CR17]\], supporting that combination therapy is tolerable in a real-world clinical practice.

We also found that the rate of overall AEs in the VM cohort (8.3%) was lower than in the comparator cohort (12.8%). Similarly, a 24-week, randomized, multicenter, crossover study in Germany showed that fewer patients with AEs were reported with VM (15%) than with other dual OAD treatment (37.1%) \[[@CR41]\]. In the present study, the frequencies of AEs were lower than that in the German study \[[@CR41]\], which might be explained by differences in study design. Indeed, in RCTs, there is usually a higher compliance than in real-world studies resulting from the stricter and regular follow-up and supervision. Whereas in real-world studies, the AEs rates are generally lower because there is no formal enquiry and they are reported by the patients themselves. Hence, the EDGE study reported that the rate of AEs was only 5.28% in the vildagliptin add-on to metformin treatment cohort \[[@CR17]\]. In the present study, no difference in cardiac disorders (VM vs. comparator, 0.1% vs. 1.3%) or nervous system disorders (including stroke; VM vs. comparator, 0.4% vs. 0.9%) was observed between the VM and comparator cohorts, which was consistent with a meta-analysis of 17,446 patients with T2DM that showed that vildagliptin was not associated with an increased risk of major adverse cardiovascular events or heart failure compared with the comparators \[[@CR42]\]. In addition, a recent trial in patients with T2DM and heart failure also showed that vildagliptin was not associated with decreased left ventricular ejection fraction, worsening of heart failure, or hospitalization due to heart failure, compared with placebo \[[@CR43]\].

This is a real-world study and therefore has some limitations. Because of no randomization in our study, there were biases and confounding factors that should be addressed. The main limitation of the study was the selection bias from the physician being responsible for selecting treatment. The treatment decisions were based on several factors and demographic characteristics, which included age, gender, BMI, ethnicity, baseline HbA1c levels, duration of T2DM, complications, smoking history, and T2DM family history. These factors may have influenced not only the choice of treatment but also the results of the study, especially in terms of safety assessment. Matching or stratified sampling might help to control these relevant factors. On the other hand, as a result of the difference of prescription patterns in the real-world setting, an important difference in age and disease duration was observed in the VM versus comparator cohorts. To preserve an adequate sample size for analysis, these factors was not adjusted in the PSM. Only a small number of patients received vildagliptin with other OADs and they were not analyzed in the present study because PSM would not have been possible. Combinations of vildagliptin with OADs like pioglitazone and glimepiride have been reported to be efficient and safe in patients with T2DM in clinical trials \[[@CR44], [@CR45]\]. Future studies will have to examine the combination of vildagliptin with OADs other than metformin in a real-world setting.

Conclusion {#Sec14}
==========

In summary, the present real-world study from China shows that compared with dual OAD non-vildagliptin combination therapies, vildagliptin add-on to metformin is effective, well tolerated, and safe for the treatment of Chinese patients with T2DM.
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